- Join thousands of UK patients finding relief with Cannabis Prescriptions UK. Book your free consultation today.
Gabapentin occupies an uncomfortable position in UK prescribing. It was introduced as a safer alternative to older neuropathic pain medications, prescribed widely for nerve pain, fibromyalgia, and restless legs syndrome, and adopted quickly across primary care. It is now a controlled drug.
That reclassification in 2019, from an unscheduled medicine to a Class C, Schedule 3 controlled substance, was not an administrative technicality. It reflected a growing body of evidence that gabapentin carries a meaningful risk of dependence and abuse that had been significantly underestimated. If you are one of the many thousands of UK patients currently taking it, understanding that context matters.
Gabapentin (brand name Neurontin) is licensed in the UK for epilepsy and peripheral neuropathic pain, though it is widely prescribed off-label for a range of pain and anxiety-related conditions.
For nerve pain, the NHS recommends a starting dose of 300mg on day one, rising to 300mg twice daily on day two, then 300mg three times daily on day three. The dose is then typically titrated upward based on response. The usual effective range for nerve pain is 900mg to 3,600mg per day, split into three doses. The maximum licensed dose is 3,600mg per day.
Because of its abuse potential, gabapentin is now subject to Schedule 3 controlled drug requirements in England, Scotland, and Wales, meaning pharmacists and prescribers must follow the same monitoring protocols applied to drugs like tramadol.
One of the most significant concerns with long-term gabapentin use is that withdrawal, when it occurs, can be severe and prolonged, more so than many patients are warned about.
Symptoms of gabapentin withdrawal include:
NICE’s clinical knowledge summary for neuropathic pain explicitly flags that gabapentin can cause dependence and that monitoring for signs of misuse or abuse is required. Despite this, the message doesn’t always reach patients at the point of prescribing, many are surprised to discover they cannot simply stop when they want to.
Tapering should be done gradually, typically reducing by no more than 300mg every 1–2 weeks, and always under medical guidance.
Medical cannabis refers to cannabis-based treatments prescribed by specialist clinicians for conditions including neuropathic pain, chronic pain, anxiety, sleep disorders, muscle spasm, and fibromyalgia, conditions that overlap substantially with gabapentin’s common use cases.
THC and CBD interact with the endocannabinoid system, modulating pain signals in a fundamentally different way from gabapentin’s GABA-analogue mechanism. For patients who have not achieved adequate relief from gabapentin or who have struggled with side effects like sedation, cognitive fog, weight gain, or swelling, this difference in mechanism opens a different therapeutic pathway.
The evidence base for cannabis-based medicines in neuropathic pain has grown considerably in recent years. A 2025 systematic review in Biomolecules examining cannabis-based medicines for neuropathic pain found consistent evidence of benefit across multiple pain types, with a particularly strong signal for peripheral neuropathic pain, one of gabapentin’s primary indications.
A large pharmacoepidemiological study published in Pain in 2021 tracked patients with neuropathic pain who received cannabis-based medicines versus matched controls, finding that cannabis users showed reduced use of other pain medications, including gabapentinoids, alongside improvements in sleep and quality of life measures.
Crucially, cannabis-based medicines showed no indications of the severe respiratory or cognitive side effects associated with high-dose gabapentin, making them a potentially relevant alternative for patients who have experienced tolerance or side-effect burden.
| Gabapentin | Medical Cannabis | |
| Mechanism | GABA-analogue; calcium channel modulation | Endocannabinoid system modulation |
| UK controlled status | Class C / Schedule 3 (since 2019) | Legal with specialist prescription since 2018 |
| Dependence risk | Moderate to high — underrecognised | Lower, but possible |
| Common side effects | Sedation, cognitive fog, weight gain, oedema | Mild dizziness, dry mouth, drowsiness at high doses |
| Withdrawal | Can be severe; seizure risk | Milder irritability, sleep disruption |
| Key indication overlap | Neuropathic pain, fibromyalgia, and sleep | Neuropathic pain, fibromyalgia, sleep, anxiety |
A pattern we see repeatedly is patients whose gabapentin was effective at the outset but has become progressively less so over time. Tolerance develops, a well-recognised phenomenon, and dose escalation brings side effects without proportionate benefit. The cognitive dulling and fatigue that many patients experience at higher doses can itself become disabling.
Medical cannabis is not automatically a better option for everyone on gabapentin. But for patients where the benefit-risk balance of gabapentin has shifted, where the drug is no longer doing enough, and the side effects have become the dominant experience, it represents a clinically relevant alternative worth discussing with a specialist.
Medical cannabis may be suitable for patients who:
A consultation with a specialist clinician can help determine whether medical cannabis may be appropriate for your condition.
They work differently in the body. Gabapentin targets nerve activity, while medical cannabis interacts with the endocannabinoid system to help regulate pain, sleep, mood, and inflammation.
Many patients explore medical cannabis for neuropathic pain and chronic nerve-related conditions.
Some patients report fewer disruptive side effects with medical cannabis compared to gabapentin, although treatment responses vary.
Some patients may use both treatments together under medical supervision. A specialist clinician can advise on safety and suitability.
Discover whether medical cannabis could help you manage chronic pain, nerve pain, sleep problems, and anxiety with a more personalised treatment approach.
Medical Disclaimer
This content is intended for general informational purposes only and does not constitute medical advice. Medical cannabis should be used under the supervision of a qualified healthcare professional in accordance with UK regulations.
